WuXi AppTec Co., Ltd. (WUXIF)
13.60
0.00 (0.00%)
USD |
OTCM |
Dec 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 40.58B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 136.4% |
| Valuation | |
| PE Ratio | 19.36 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.555 |
| Price to Book Value | 4.071 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0490 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.1281 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 84.37% |
Profile
| WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China. |
| URL | http://www.wuxiapptec.com.cn |
| Investor Relations URL | N/A |
| HQ State/Province | Shanghai |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 16, 2026 (est.) |
| Last Earnings Release | Oct. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 10, 2025 |
Ratings
Profile
| WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China. |
| URL | http://www.wuxiapptec.com.cn |
| Investor Relations URL | N/A |
| HQ State/Province | Shanghai |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 16, 2026 (est.) |
| Last Earnings Release | Oct. 26, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Sep. 10, 2025 |